RxDoctor Payments Data

Ayan Patel, MD

Cardiovascular Disease · Boston, MANPI 1720013865

Payments from drug & device makers

$87,756in general payments, 2019–2025

Across 79 payments — averaging $1110.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$46K
  • Pfizer$19K
  • Astrazeneca UK Limited$18K
  • Bridgebio Pharma, Inc.$3K
  • AstraZeneca$2K
  • Sanofi$1K

What the payments were for

  • Consulting fees$61,52097%
  • Speaking & faculty fees$1,6473%
  • Food & beverage$4411%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Livanova USA, Inc.49$46,011
Pfizer21$18,522
Astrazeneca UK Limited2$17,515
Bridgebio Pharma, Inc.2$2,763
AstraZeneca1$1,611
Sanofi4$1,333

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,756 in reported general payments places this provider in the 85th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$85,886
Medicare patients
890
Services billed
1,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis347$9,101,743
VyndaqelTafamidis Meglumine15$298,954
JardianceEmpagliflozin52$45,906
FarxigaDapagliflozin Propanediol22$26,522
Repatha SureclickEvolocumab40$25,722
Praluent PenAlirocumab19$9,424
Metoprolol Succinate52$1,238
Ezetimibe23$739
Isosorbide Mononitrate ErIsosorbide Mononitrate12$574
Furosemide38$444
Atorvastatin Calcium37$442
Torsemide15$394
Rosuvastatin Calcium17$342
Lisinopril45$263
Spironolactone16$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel$18,522$9,400,698362 claims
AstraZenecaFarxiga$1,611$26,52222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →